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OBJECTIVES This study examined the effects of endotoxin on cardiac contractility in human myocardium.
BACKGROUND In animal myocardium, endotoxin and cytokine treatment led to enhanced inducible nitric
oxide synthase (iNOS) expression and contractile dysfunction. Effects in human myocardium
are unknown.
METHODS Left ventricular myocardial preparations from failing (n 5 18) and nonfailing (n 5 5) human
hearts were incubated for 6 and 12 h in tyrode solution or in tyrode plus lipopolysaccharides
(LPS), with LPS plus NG-mono-methyl-L-arginine (L-NMMA), with LPS plus hemoglobin
or with LPS plus the superoxide scavenger 4,5-dihydroxy-1,3-benzene disulfonic acid
(Tiron). Force of contraction in response to isoprenaline (0.001 to 3 mmol/liter) was
determined in electrically stimulated muscle preparations. The iNOS mRNA expression was
examined by in situ hybridization and by polymerase chain reaction. The cyclic guanosine
monophosphate (cGMP) levels were determined by radioimmunoassay.
RESULTS Isoprenaline concentration dependently increased force of contraction. Six and 12 hours of
LPS treatment of failing myocardium decreased maximum inotropic response to isoprenaline
by 54% (p 5 0.009) and by 69% (p 5 0.0023), respectively. In nonfailing myocardium, 12 h
of LPS treatment decreased maximum inotropic effect of isoprenaline by 66% (p , 0.001).
The LPS effects were attenuated by L-NMMA, hemoglobin and also Tiron. The iNOS
mRNA was expressed in all LPS-treated preparations but also in most control myocardial
preparations. In situ hybridization revealed iNOS expression within cardiac myocytes. There
was no increase in myocardial cGMP content in response to endotoxin.
CONCLUSIONS Endotoxin exposure of human myocardium leads to a depression of cardiac contractility,
which is mediated by enhanced iNOS activity and release of nitric oxide (NO). Consecutive
reaction of NO with superoxide and formation of peroxynitrite may contribute to the decrease
in force of contraction. (J Am Coll Cardiol 1999;33:1062–70) © 1999 by the American
College of Cardiology
Septic shock as part of the “systemic inflammatory response
syndrome” is the predominant cause of mortality due to
multiple organ failure on intensive care units (1). Impair-
ment of cardiac contractility is part of this multiple organ
dysfunction syndrome (2).
Several mechanisms contribute to the impairment of
cardiac function. The existence of a cardiodepressant factor
in septic serum has been postulated (3). Increased plasma
catecholamine levels (4) might lead to catecholamine refrac-
toriness by desensitization of b-adrenoceptors due to an
increase in inhibitory G-proteins (5) and a decrease in
b-adrenoceptor density (6).
New insights into the pathophysiology of septic shock
have been provided by the discovery that endotoxins alone
or in combination with cytokines can induce the production
of large amounts of nitric oxide (NO), predominantly by an
enhanced expression of the inducible isoform of NO syn-
thase (iNOS) (for review see Kelly et al. [7]). Finkel et al.
(8) demonstrated a NOS-mediated negative inotropic effect
of cytokines in hamster papillary muscles. In hearts from
endotoxin-treated animals and in isolated myocytes, en-
hanced iNOS expression has been demonstrated in response
to IL-1b, IFN-g, IL-6 and TNF-a or to lipolysaccharides
(9–14) leading to contractile dysfunction, which could be
prevented by NOS-inhibitors (8–10). These observations
suggest that enhanced formation of NO—possibly followed
From the Klinik III fu¨r Innere Medizin, *Klinik fu¨r Herz- und Thoraxchirurgie,
†Pathologisches Institut, der Universita¨t zu Ko¨ln, and the ‡Institut fu¨r Pharmakolo-
gie und Toxikologie, der Westfa¨lischen Wilhelms-Universita¨t, Mu¨nster, Germany.
Experimental work was financially supported by the Deutsche Forschungsgemein-
schaft (M.B.) and the Laerdal Foundation (M.B., M.F.). This work contains data of
the doctoral theses of H.K. and B.C. (University of Cologne, in preparation).
Manuscript received February 27, 1998; revised manuscript received September 1,
1998, accepted December 7, 1998.
Journal of the American College of Cardiology Vol. 33, No. 4, 1999
© 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00
Published by Elsevier Science Inc. PII S0735-1097(98)00660-3
by activation of guanylyl cyclase (10,15)—might be respon-
sible for impaired cardiac contractility.
This view has recently been challenged by Keller et al.
(16) and Decking et al. (17), who did not observe an
attenuation of depressed contractility by NOS inhibitors
and an increase in iNOS activity in isolated left atrial
preparations and in isolated ventricular myocytes from
endotoxin-treated guinea pigs. Thus, there is still a contro-
versy about the importance of NOS-induction for the
development of septic cardiomyopathy. In particular, this
controversy holds true for the situation in humans. There is
evidence that iNOS expression is increased in hearts from
septic patients (18) and during cardiac allograft rejection
(19). Also, in human cardiac allografts, an association has
been demonstrated between iNOS expression and contrac-
tile dysfunction (20). However, it has so far not been
elucidated whether endotoxin exposure of human myocar-
dium causes an impairment of cardiac contractility, which is
independent from systemic circulatory changes, and
whether in human myocardium endotoxin or cytokines lead
to an induction of NOS.
To address these questions, an in vitro model of human
endotoxemic cardiomyopathy was established by treating hu-
man left ventricular myocardium with endotoxin. In the
endotoxin-treated myocardium, isometric force of contraction,
iNOS mRNA expression, myocardial cyclic guanosine mono-
phosphate (cGMP) levels and functional effects of the NOS
inhibitor (NG-mono-methyl-L-arginine), the NO-scavenger
hemoglobin and the free radical-scavenger Tiron (4,5-
dihydroxy-1,3-benzene disulfonic acid) were investigated.
METHODS
Human myocardial tissue. Experiments were performed
on left ventricular myocardium from 18 failing (5 ischemic
cardiomyopathy, 13 dilative cardiomyopathy) and 5 nonfail-
ing human hearts obtained during cardiac transplantation.
Nonfailing hearts were obtained from organ donors. These
hearts were used for pulmonary and aortic valve allograft
preparation because there was no appropriate recipient
available for cardiac transplantation. Mean age of organ
donors (3 men, 2 women) was 34.4 6 7 years; mean age of
organ recipients (16 men, 2 women) was 46.8 6 3 years.
The mean ejection fraction of organ recipients before
operation was 24.4 6 1%. Organ donors and recipients had
no signs of bacterial infection or sepsis. Medical therapy of
the patients with end-stage heart failure consisted of cardiac
glycosides, diuretics, nitrates and angiotensin-converting
enzyme (ACE) inhibitors. General anesthesia was per-
formed with flunitrazepam, fentanyl and pancuronium bro-
mide with isoflurane. Cardiac surgery was performed while
on cardiopulmonary bypass. Only noninfarcted tissue was
used, and scars were carefully trimmed away. Tissue pieces
were suspended in ice-cold cardioplegic solution (modified
Bretschneider solution containing (in mmol/liter): NaCl 15,
KCl 10, MgCl2 4, histidine HCl 180, tryptophan 2,
mannitol 30 and potassium dihydrogen oxyglutarate 1) and
were delivered immediately from the operation room to the
laboratory.
Isolated left ventricular muscle strip preparation and
incubation conditions. Left ventricular muscle strips of
uniform size with muscle fibers running approximately
parallel to the length of the strips were dissected under
microscopic control using scissors in ice-cold aerated mod-
ified Tyrode solution (composition below). Connective
tissue was carefully trimmed away. The muscles were
suspended in an organ bath (75 ml) maintained at 37°C and
containing a modified Tyrode solution of the following
composition (in mmol/liter): NaCl 119.8; KCl 5.4; MgCl2
1.05; CaCl2 1.8; NaHCO3 22.6; NaH2PO4 0.42; glucose
5.0; ascorbic acid 0.28; EDTA 0.05. The bathing solution
was continuously aerated with 95% O2 and 5% CO2.
Tyrode solution was supplemented with either lipopolysac-
charide (LPS) from Salmonella typhosa (1 mg/ml), with
endotoxin plus N G-mono-methyl-L-arginine (L-NMMA,
100 mmol/liter), with endotoxin plus hemoglobin (2 mg/ml)
and with endotoxin plus 4,5-dihydroxy-1,3-benzene disul-
fonic acid (Tiron, 10 mmol/liter) or was used without
supplementation for control experiments. Under these con-
ditions, left ventricular myocardial preparations were either
incubated for 6 or 12 h. Immediately after incubation, some
of the ventricular muscle preparations were used for func-
tional experiments, whereas others were frozen by rapid
immersion into liquid nitrogen and stored at 280°C.
For control purposes, microscopic analysis of the incu-
bated muscle preparations was performed on hematoxylin-
eosin and Luxol fast blue stained cryostat sections. In
general, histological examination revealed the microscopic
features as expected from the preexisting myocardial disor-
der (e.g., marked hypertrophy of the cardiomyocytes of
patients with dilated cardiomyopathy). There was no mor-
phologic evidence of acute ischemic or toxic myocardial
injury or structural alterations in any of the tissue pieces
independent from whether myocardial preparations were
incubated in unsupplemented Tyrode solution or in Tyrode
solution supplemented with endotoxin, endotoxin plus
L-NMMA or endotoxin plus Tiron.
Determination of force of contraction. For determination
of isometric force of contraction, myocardial preparations
were stimulated by two platinum electrodes using field
stimulation from a Grass S88 stimulator (Grass, Quincy,
Massachusetts; frequency 1 Hz; impulse duration 5 ms;
Abbreviations and Acronyms
cGMP 5 cyclic guanosine monophosphate
iNOS 5 inducible nitric oxide synthase
NO 5 nitric oxide
O2
2 5 superoxide
ONOO2 5 peroxynitrite
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intensity 10% to 20% greater than threshold). Experiments
were performed in Tyrode solution at 37°C. Each muscle
was stretched to the length at which force of contraction was
maximal. Isometric tension was measured with an inductive
force transducer (W. Fleck, Mainz, Germany) attached to a
Gould recorder (Gould, Cleveland, Ohio). Preparations
were allowed to equilibrate for at least 90 min, with the
bathing solution being changed once after about 45 min.
Detection of iNOS mRNA by in situ hybridization. For
histological localization of iNOS by in situ hybridization,
6-mm thin cryosections of the pretreated myocardium were cut
and mounted on slides that had been sterilized and pretreated
with 3-aminopropyltriethyoxysilan. Slides were used for in situ
hybridization immediately or dehydrated by an ethanol series
and stored at 280°C. Before hybridization, sections were fixed
in 4% paraformaldehyde in phosphate-buffered saline, pH 7.4
(PBS), washed twice with PBS and treated with proteinase K
(20 mg/ml in Tris/EDTA buffer) for 7 min, washed in PBS,
postfixed in 4% paraformaldehyde in PBS, washed twice in
PBS and 0.9% NaCl for 5 min each.
A full-length macrophage inducible NOS cDNA (21),
which was kindly donated by Prof. Lowenstein (Baltimore,
Maryland), was used for probe preparation. The cDNA was
cloned into the Not 1 site of the Strategene vector Bluecript
KS1 (Stratagene, Heidelberg, Germany). After lineariza-
tion with Eco RV, 35S-labeled 500-bp antisense cRNA
were generated by in vitro transcription using the T3 RNA
polymerase. The 700-bp cRNA probes in sense orientation
were transcribed after linearization with Dra I with the T7
RNA polymerase to serve as negative controls in each series
of experiments. Incorporated label was purified by gel
filtration. Some sections were hybridized with a cRNA
probe specific for intercellular adhesion molecule-1
(ICAM-1) as described elsewhere (22).
Sections were prehybridized in hybridization solution
(50% formamide, 10% dextransulfate, 10 mmol/liter Den-
hard solution (Ficoll, polyvinylpyrrolidone, and bovine se-
rum albumin; 1 mg/ml each), 0.9 mol/liter NaCl, 60 mmol/
liter Na2HPO4, 6 mmol/liter EDTA, 0.5% SDS, and
200 mg/ml tRNA from yeast) for 1 to 2 h in a humid
chamber (50% formamide). Denatured cRNA probes
(5 min, 65°C) were added to fresh hybridization solution at
a concentration of 700,000 dpm/50 ml. Hybridization was
performed for 10 to 14 h at 50°C. Sections were washed
twice for 10 min in 23 standard saline citrate (SSC) with
20 mmol/liter mercaptoethanol at 50°C, twice for 5 min in
23 SCC with 10 mmol/liter Tris and 1 mmol/liter EDTA
(23 SSCTE) at 50°C, for 30 min in 23 SSCTE plus
10 mg/ml RNase A and 10 U RNase T1 at 37°C, once for
5 min 0.23 SSC at 37°C and twice for 15 min to a final
stringency of 0.23 SSC at 65°C. The sections were dehy-
drated in an ethanol series in the presence of 300 mmol/liter
ammonium acetate, air-dried for 10 min, and exposed to
Kodak X-omat AR X-ray film for 3 days to get an
orientation about the signal intensity. Afterwards, sections
were coated with undiluted Kodak NTB-2 photoemulsion
at 45°C. After 3 to 4 weeks of exposure at 4°C, the
emulsion-coated slides were developed in Kodak D-19
(16 g/l), fixed in Kodak Unifix (150 g/l), and counterstained
lightly with hematoxylin-eosin.
Determination of iNOS mRNA expression by RT-PCR.
The RNA (2 mg) was reverse-transcribed to give cDNA in
a final volume of 30 ml containing Tris-HCl 10 mmol/liter
(pH 8.3), KCl 50 mmol/liter, MgCl2 5 mmol/liter, random
hexamers 1.7 mmol/liter, 0.5 mmol/liter each of dATP,
dTTP, dCTP and dGTP, RNase inhibitor 0.5 mmol/liter
and Moloney murine leukemia virus reverse transcriptase
3.3 U/ml. The reaction was carried out at 42°C for 1 h,
followed by heat inactivation of the enzyme at 75°C for
10 min. The cDNA was stored at 280°C.
Polymerase chain reaction (PCR) was performed using
specific primers (Clontech, Heidelberg, Germany) yielding
a PCR product of 259-base pair length leading from
nucleotide 3589 to nucleotide 3848 of the human iNOS
sequency published by Geller et al. (23). Primer sequences
were: 59-CGG TGC TGT ATT TCC TTA CGA GGC
GAA GAA GG-39 and 59-GGT GCT ACT TGT TAG
GAG GTC AAG TAA AGG GC-39. The PCR was
performed in Tris HCl 10 mmol/liter, MgCl2 1.5 mmol/liter,
KCl 50 mmol/liter, dNTPs 160 mmol/liter, primers 10
pmol/liter and Taq-polymerase 1.25 IE/50 ml. After an
initial cycle of 3 min at 94°C, 2 min at 64°C and 1 min at
72°C, reactions were performed for 35 cycles consisting of a
1-min denaturation step at 94°C, an annealing step of 1 min
at 64°C and a synthesis step of 1 min at 72°C. The PCR was
finished by a final extension step at 72°C of 7 min.
Reactions were performed on a Perkin-Elmer Thermal
cycler 480 (Perkin-Elmer, U¨berlingen, Germany). To con-
trol adequate isolation of RNA and conversion to cDNA,
amplification of GAPDH was performed using the follow-
ing primers: 59-GCT TTT AAC TCT GGT AAA GTG
G-39 and 59-TCA CGC CAC AGT TTC CCG GAG
G-39. PCR products were visualized by ethidium bromide
staining after agarose gel electrophoresis. Identity was also
confirmed by automatic sequencing of the PCR product
using the following internal primer: 59 GTG CAG CCC
AGC AGC CTG -39.
Determination of myocardial cGMP content. For deter-
mination of myocardial cGMP content, frozen myocardial
tissue was pulverized and solubilized in 6% (v/v) trichloro-
acetic acid containing 10 mmol/liter HCl yielding a final
concentration of 100 mg tissue in 1000 ml solution. After
centrifugation at 2000 g over 15 min, the supernatant was
washed with water-saturated diethylether to remove trichlo-
roacetic acid. Afterwards, the cGMP-containing liquid
phase was lyophilized. Determination of the cGMP content
in the ventricular myocardium was performed using a
commercially available radioimmunoassay (Amersham-
Buchler, Braunschweig, Germany). To have a positive
control, right atrial trabecula obtained during open heart
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surgery were acutely exposed to the NO-donator sodium
nitroprusside (SNP, 100 mmol/liter). For cGMP content
determination, atrial trabecula were essentially handled the
same as ventricular preparations.
Materials. Lipopolysaccharides from Salmonella typhosa,
N G-mono-methyl-L-arginine (L-NMMA), 4,5-dihydroxy-
1,3-benzene disulfonic acid (Tiron) and hemoglobin were
purchased from Sigma-Aldrich (Deisenhofen, Germany).
Molecular biology enzymes were all purchased from Boehr-
inger (Mannheim, Germany) if not indicated otherwise. All
chemicals used were of analytical grade or the best grade
commercially available. All compounds were dissolved in
deionized and twice-distilled water.
Statistics. The data shown are means 6 SEM; EC50 values
are given as means 6 95% confidence intervals. For statis-
tical analyses of concentration-response curves, area under
the curves (AUCs) were calculated and analyzed by
ANOVA. The least significant difference (LSD) test and
the Shaffer procedure were used for the multiple pairwise
comparisons (i.e., if the F test of the global hypothesis was
significant, the one-sided p values of the pairwise compar-
isons were calculated by the LSD test and compared with
Shaffer’s significant levels [a/3, a/3, a/3, a/3, a/2, a]).
RESULTS
Acute effects of endotoxin on force of contraction. The
addition of increasing concentrations of endotoxin (0.001 to
3 mg/ml) had no acute effect on basal isometric force of
contraction. Also, the concentration-dependent increase in
force of contraction in response to increasing concentrations
of isoprenaline (0.001 to 3 mmol/liter) was not affected by
acute addition of endotoxin (1 mg/ml) into the organ bath.
Effect of endotoxin treatment on force of contraction in
failing myocardium. Six and 12 hours’ incubation of myocar-
dial preparations in Tyrode solution supplemented with LPS
led to a significant attenuation of the concentration-dependent
increase in force of contraction in response to isoprenaline
(0.001 to 3 mmol/liter) compared to preparations incubated in
unsupplemented Tyrode solution. Six hours’ endotoxin treat-
ment of failing myocardium decreased the maximum inotropic
effect of isoprenaline by 54% (p 5 0.0087; Fig. 1, upper panel);
12-h treatment decreased it by 69% (p 5 0.0023; Fig. 1, lower
panel). There was no change in the potency of isoprenaline due
to endotoxin treatment as indicated by EC50 values (12-h
incubation, control vs. endotoxin: 0.044 (0.030 to 0.064)
mmol/liter and 0.065 (0.039 to 0.108) mmol/liter).
Effect of L-NMMA and hemoglobin on force of contrac-
tion. To investigate whether the decreased inotropic re-
sponse to isoprenaline and the decrease in basal contractility
following endotoxin treatment might be mediated by acti-
vation of NOS, the effect of co-incubation of the ventricular
preparations with endotoxin and the NOS-inhibitor
L-NMMA and of co-incubation with endotoxin and the
NO-scavenger hemoglobin was determined. L-NMMA sig-
nificantly attenuated the effects of endotoxin on myocardial
force generation. Similarly, hemoglobin attenuated the ef-
fect of endotoxin treatment, although this effect did not
reach statistical significance (Fig. 1).
Effect of endotoxin treatment on force of contraction in
nonfailing myocardium. The relative concentration-
dependent effect of isoprenaline on isometric force of
contraction was more pronounced in nonfailing than in
failing myocardium, the maximum increase in force of
contraction in response to isoprenaline being 523 6 58% in
nonfailing (n 5 10) and 339 6 37% (n 5 17) in failing
myocardium (p 5 0.009) (Fig. 2, A). Twelve hours of
endotoxin treatment of nonfailing left ventricular myocar-
dium decreased the maximum inotropic response to iso-
prenaline by 66% (p , 0.001 endotoxin vs. control). The
effect was similar to the endotoxin effect in failing myocar-
dium (Fig. 2, B). Co-incubation of nonfailing myocardium
Figure 1. Effect of treatment of isolated human left ventricular
myocardial preparations from terminally failing hearts with lipo-
polysaccharides (Endo, 1 mg/ml) on the concentration-dependent
inotropic response to isoprenaline. Upper panel shows the effect of
6 h and lower panel the effect of 12 h of incubation. Also, the
effects of co-incubation of isolated myocardial preparations with
either L-NMMA (100 mmol/liter) or hemoglobin (Hb, 2 mg/ml)
are demonstrated. Ordinate gives force of contraction in mN,
abscissa concentration of isoprenaline in mmol/liter. Data are given
as mean 6 SEM.
1065JACC Vol. 33, No. 4, 1999 Flesch et al.
March 15, 1999:1062–70 Nitric Oxide and Peroxynitrite in Septic Cardiomyopathy
with L-NMMA significantly attenuated the endotoxin ef-
fect. Again, there was no effect of endotoxin treatment on
the potency of isoprenaline (EC50 values: control 0.027
(0.016 to 0.046) mmol/liter vs. endotoxin 0.046 (0.028 to
0.074) mmol/liter).
Detection of iNOS mRNA in incubated left ventricular
myocardial preparations. Also, to investigate whether the
decrease in myocardial force development could be ex-
plained by an enhanced expression of iNOS in response to
endotoxin treatment, presence of iNOS mRNA in control
myocardium and endotoxin-treated myocardium was deter-
mined by RT-PCR and by in situ hybridization.
The RT-PCR with specific primers for iNOS led to the
amplification of a cDNA segment corresponding in its
electrophoretic migration characteristics to the expected
iNOS cDNA segment of 259-bp length (Fig. 3). Identity of
the PCR product with the expected cDNA fragment was
confirmed by sequence analysis (not shown). In failing
myocardium, iNOS mRNA was detectable in all samples
(6/6) independent from whether samples were treated with
endotoxin or not. Similarly, in the majority of samples from
nonfailing hearts (4/6), iNOS mRNA was already detect-
able in those samples that had not been exposed to endo-
toxin. In samples from two nonfailing hearts in which iNOS
mRNA was not already present in tyrode-incubated con-
trols, a iNOS PCR product was obtained after treatment
with endotoxin.
In situ hybridization revealed specific signals for iNOS
mRNA in cardiac myocytes as well as in non-myocyte cells
(Fig. 4). The signal obtained from cardiac myocytes was
much denser than the signal obtained from other cell types,
indicating that iNOS is predominantly expressed in cardiac
myocytes. In contrast, the hybridization signal for intercel-
lular adhesion molecule-1 (ICAM-1) used as a control was
mainly expressed in endothelial cells along intramyocardial
blood vessels and was not reliably detectable in cardiac
myocytes (not shown). Thus, the predominant expression of
iNOS mRNA within cardiac myocytes is not due to a
selective loss of endothelial cells during the incubation
procedure.
Determination of myocardial cGMP content. Myocar-
dial cGMP content was determined in left ventricular
myocardial preparations that were incubated in parallel to
muscle preparations used for functional experiments. Nei-
ther after 6 h nor after 12 h of incubation was an increase in
myocardial cGMP level detectable (Fig. 5).
Figure 2. Comparison of the effect of lipopolysaccharide treatment for 12 h on the concentration-dependent inotropic response of failing
and nonfailing left ventricular myocardial preparations to isoprenaline. (A) This shows the inotropic response to isoprenaline after
incubation of myocardial preparations in normal tyrode (control); (B) shows the inotropic response to isoprenaline after incubation in
tyrode supplemented with lipopolysaccharides (Endo, 1 mg/ml). Data are given as mean 6 SEM.
Figure 3. Result of iNOS mRNA detection by RT-PCR in left
ventricular myocardial preparations from two nonfailing hearts
incubated for 12 h either in normal tyrode solution (control) or in
tyrode plus lipopolysaccharides (1 mg/ml). Amplification products
of iNOS-PCR were loaded on the left side, those of GAPDH-
PCR on the right side of the gel. Notice that only in two of six
nonfailing hearts shown in this figure, iNOS mRNA was not
already detectable in control samples, and that iNOS mRNA was
detectable in all samples from failing hearts (n 5 6).
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Effect of co-incubation of myocardial preparations with
endotoxin and Tiron. To investigate whether oxygen-
derived free radicals (O2
2) and formation of peroxynitrite
(ONOO2) contribute to endotoxin-induced contractile
dysfunction, the effect of the superoxide (O2
2) scavenger
Tiron was investigated. Also, in this independent series of
experiments, endotoxin treatment of human myocardial
preparations for 6 h led to a pronounced decrease in the
concentration-dependent positive inotropic response to iso-
prenaline by a maxim of 50% (p 5 0.035, t test) (Fig. 6).
The addition of Tiron to the incubation medium abolished
the effect of endotoxin on myocardial contractility (Fig. 6).
Incubation with Tiron alone had no effect on the inotropic
response to isoprenaline (Fig. 6).
DISCUSSION
The present study investigated whether cardiac contractile
dysfunction in endotoxin shock might be a direct conse-
quence of endotoxin exposure of the myocardium and which
cellular mechanisms may be involved in the pathophysiology
of septic cardiomyopathy.
Inotropic effects of endotoxin in human nonfailing and
failing myocardium. Treatment of isolated human left
ventricular myocardium for 6 or 12 h with endotoxin led to
a decrease in basal and isoprenaline-enhanced force of
contraction. The effect was attenuated by the NO-synthase
inhibitor L-NMMA and abolished by the superoxide scav-
enger Tiron, indicating that negative inotropism of endo-
toxin is mediated by enhanced release of NO and possible
interaction with oxygen-derived radicals.
Figure 4. Result of iNOS mRNA detection in human myocardial
preparations by in situ hybridization. Hybridized slides is shown
from endotoxin-treated myocardium. Notice that the specific
iNOS hybridization signal can mainly be depicted from cardiac
myocytes.
Figure 5. Bar graph demonstrating the effect of endotoxin treat-
ment (Endo, 1 mg/ml, 6 and 12 h) of human ventricular myocar-
dial preparations in the absence or presence of L-NMMA (100
mmol/liter) on myocardial cGMP content. Acute treatment of
atrial trabecula with sodium nitroprusside (SNP, 100 mmol/liter)
was performed as a control. Six hours of incubation: n 5 6 per
condition; 12 h of incubation: n 5 10 per condition, atrial
preparations: n 5 10 per condition. Ordinate: cGMP concentra-
tion in fmol/mg wet weight. Data are given as mean 6 SEM.
Figure 6. Effect of co-incubation of human left ventricular myo-
cardial preparations for 6 h either with lipopolysaccharides (1
mg/ml, n 5 5), with lipopolysaccharides and the radical-scavenger
Tiron (10 mmol/liter, n 5 5), with Tiron (10 mmol/liter, n 5 5)
alone or in normal Tyrode (control, n 5 5). Upper panel shows
the concentration-dependent positive inotropic effect of isoprena-
line. Ordinate gives force of contraction in mN, abscissa gives
isoprenaline concentrations in mmol/liter. Bar graph in the lower
panel summarizes the maximum isoprenaline effects on isometric
force of contraction in the different groups.
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Suffredini et al. (24) were the first to demonstrate that
endotoxin-treatment led to a depression of left ventricular
contractility in humans. The limitation of their examination
was that administration of endotoxin in vivo did not allow
them to discriminate between direct effects of endotoxin in
the myocardium and indirect effects such as alterations in
peripheral vascular resistance or toxic effects of released
catecholamines or cytokines. In contrast, the present study
provides evidence that prolonged endotoxin treatment is
sufficient to directly induce contractile dysfunction in hu-
man myocardium.
The negative effect of endotoxin treatment on basal force
of contraction and the inotropic response to isoprenaline
was present in both nonfailing and failing myocardium.
Thus, endotoxin also leads to a decrease in force of
contraction in myocardial preparations in which force of
contraction and especially the inotropic response to isopren-
aline is already impaired (25) and in which NOS activity is
already enhanced (26–28) as has been reported previously
for failing human myocardium. Therefore, enhanced NOS
expression and activity in heart failure does not seem to be
a yes or no effect, but a gradual and modifiable effect that
progressively leads to an impairment of cardiac function.
Molecular evidence for iNOS mRNA expression in
response to endotoxin treatment. Findings in animal
models of endotoxin- or cytokine-induced cardiomyopathy
indicate that induction of iNOS is one key mechanism to
produce cardiodepressant effects (7,9–11,14). In accor-
dance, iNOS mRNA could be detected within human
myocardium by RT-PCR and in situ hybridization in the
present study. However, no significant difference was seen
between iNOS mRNA signals from endotoxin-treated and
from control myocardium as determined either by in situ
hybridization or by RT-PCR. In failing myocardium in
which enhancement of iNOS expression and activity has
already been demonstrated (26–28), one might have ex-
pected this finding. However, also in the nonfailing myo-
cardium, iNOS mRNA was already detectable in most of
the samples treated in Tyrode without endotoxin supple-
mentation. One explanation might be that, according to a
previous report (27), iNOS gene expression can be observed
in more than 50% of nonfailing donor hearts, which might
be due to medical treatment before, or handling of the
hearts following, explanation. Alternatively, one has to
consider that endotoxin contamination of incubation basins
and media could also have contributed to iNOS induction in
control preparations.
The next question was in which myocardial cells does
iNOS expression occur and whether NO effects on cardiac
myocytes are rather paracrine or autocrine. Results of in situ
hybridization for iNOS mRNA indicate that mRNA ex-
pression occurs in all cell types including fibroblasts and
endothelial cells, but especially within cardiac myocytes
from which the strongest signal was obtained. The obser-
vation that iNOS mRNA is primarily present in cardiac
myocytes in human myocardium is in accordance with
recent findings by Haywood et al. (27), who also detected
iNOS within cardiac myocytes by immunohistochemical
staining of human myocardium. Thus, NO can be gener-
ated within cardiac myocytes themselves, and NO effects on
myocyte contractility are rather autocrine than paracrine.
Functional evidence for enhanced NOS activity. Because
RT-PCR and in situ hybridization did not allow us to quantify
differences between iNOS and mRNA levels, the question
whether endotoxin treatment of human myocardium leads to
an enhanced iNOS activity had to be addressed by functional
experiments. In this context, the effects of the NOS-inhibitor
L-NMMA and of the NO scavenger hemoglobin were exam-
ined. The addition of both the NOS inhibitor and of the
NO-scavenger to the incubation medium attenuated the en-
dotoxin effect in failing and nonfailing myocardium. This
observation from functional experiments indicates that endo-
toxin effects are mediated by enhancement of NOS activity and
formation of NO. Because contractile dysfunction in response
to endotoxin did not develop acutely, but only after prolonged
incubation, one has to assume that endotoxin leads to an
increase especially in iNOS gene expression, which might have
been overlooked by the molecular methods chosen for this
study.
Conversely, NOS inhibition did not lead to a complete
blockade of the endotoxin effects on human myocardium.
This distinguishes the recent findings from observations in
isolated myocytes (9,10,14) or isolated perfused hearts (29)
in which effects of endotoxin or cytokine on contractility
were abolished by NOS inhibition. There may be species
differences or even other mechanisms not yet known that
contribute to endotoxin-induced contractile dysfunction,
which are independent from release of NO. However, the
most likely explanation is that penetration of L-NMMA
into the multicellular myocardial preparations used for the
present experiments was less effective than penetration in
isolated myocytes used in previous experiments.
Myocardial cGMP levels in response to endotoxin. Also,
in contrast to observations in other species in which
endotoxin- or cytokine-induced contractile dysfunction was
accompanied by an increase in myocardial or myocyte
cGMP levels (10,13), no increase occurred in myocardial
cGMP levels in response ro endotoxin treatment in human
myocardium. One explanation for this discrepency with
previous reports is that the peak increase in NO release and
myocardial cGMP levels was missed because it occurs earlier
as after 6 or 12 h of endotoxin exposure. In this context, it
has been demonstrated that once established, cytokine-
induced contractile dysfunction persists even if NOS is
inhibited later on (29). One also has to consider that there
are unrelated effects of endotoxin that lower cGMP levels or
that expression of iNOS mRNA in most of the examined
samples led to an elevation of baseline cGMP levels.
However, the most likely explanation is that enhanced
iNOS activity and NO formation impair myocardial con-
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tractility by a mechanism that is independent from activa-
tion of guanylyl cyclase. This view is supported by the recent
observation that the NO-induced reduction in the contrac-
tility of isoprenaline-stimulated rat hearts could not be
modified by a guanylyl cyclase inhibitor (30).
Involvement of O2
2 and ONOO2 in endotoxin-induced
contractile dysfunction. One alternative mechanism by
which NO leads to a decrease in force of contraction is the
formation of peroxynitrite (ONOO2) (31), which is formed
by the reaction of NO with superoxide anions (O2
2) (32)
and has been demonstrated to be released from activated
macrophages as a result of the simultaneous generation of
NO and O2
2 (33). There is evidence that similar to NO
(34) ONOO2 inhibits rat heart mitochondrial respiration
(35). In contrast to the effects of NO, effects of ONOO2 on
cardiac contractility and mitochondrial respiration show no
rapid reversibility; thus, ONOO2 might be the more
pathological radical (36,37). In response to endotoxin treat-
ment, ONOO2 formation in association with enhanced
iNOS activity has been demonstrated in rat aorta in vivo
(38).
The hypothesis that endotoxin-induced contractile dys-
function in human myocardium could be mediated by the
formation of ONOO2 is supported by the finding that the
effect of endotoxin was abolished in the presence of Tiron,
a chelate complex forming and antioxidant substance that
scavenges O2
2 and ONOO2 (36,39). Obviously, one has to
consider that a radical scavenger also unselectively scavenges
NO. However, there is evidence that Tiron does not
interfere with the effects of NO or hydroxyl radicals (OH2)
(36,39). Because the effects of endotoxin could be antago-
nized by both NOS inhibition and scavenging of O2
2 and
ONOO2, one might assume that endotoxin leads to an
increased release of NO and by reaction of NO with O2
2 to
the formation of ONOO2. Formation of ONOO2 would
also explain the missing increase in myocardial cGMP levels
in response to endotoxin treatment and NO release because
reaction of NO with O2
2 might have channeled NO away
from its target guanylyl cyclase, as has been demonstrated in
human artery and vein preparations in vitro (40).
Conclusions. The results of this study demonstrate that
endotoxin exposure of human myocardium impairs cardiac
contractility independently from systemic endotoxin effects.
This impairment of myocardial performance appears to be
mediated by an enhanced release of NO and a consecutive
enhanced formation of ONOO2. The use of specific
scavengers of O2
2 and ONOO2 might lead to the devel-
opment of new therapeutic strategies for cardiac contractile
dysfunction in septic shock and inflammatory heart diseases.
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